-
公开(公告)号：US20140012177A1
公开(公告)日：2014-01-09
申请号：US13716763
申请日：2012-12-17
Applicant: DOSE MEDICAL CORPORATION
Inventor： Hosheng Tu , Barbara A. Niksch , David S Haffner , Gregory T Smedley , Olav B. Bergheim , Morteza Gharib
IPC: A61F9/007
CPC classification number: A61F9/00781 , A61F9/0017 , A61F2250/0067 , A61L27/54 , A61L2300/258 , A61L2300/41 , A61L2300/414 , A61L2300/416 , A61L2300/42 , A61L2430/16 , A61M27/002
Abstract: Implants and methods for treating ocular disorders are provided. One method involves introducing an implant into an anterior chamber of an eye. The implant is implanted into eye tissue adjacent the anterior chamber such that a proximal end of the implant resides in the anterior chamber following implantation. A therapeutic agent is eluted from the implant into the eye. Desirably, the release of the therapeutic agent from the implant is controlled. The controlled release of the therapeutic agent can be at a chosen rate and/or for a selected duration which can be episodic or periodic. The therapeutic agent can be an antiproliferative agent, an anti-inflammatory drug, or a compound for treating glaucoma or ocular hypertension.
Abstract translation: 提供了用于治疗眼部疾病的植入物和方法。 一种方法是将植入物引入眼睛的前房。 将植入物植入邻近前房的眼组织中，使植入物的近端位于植入后的前房。 治疗剂从植入物中洗脱到眼睛中。 理想地，治疗剂从植入物的释放受到控制。 治疗剂的受控释放可以是选择的速率和/或选择的持续时间，其可以是情景性的或周期性的。 治疗剂可以是抗增生剂，抗炎药或治疗青光眼或高眼压症的化合物。
-
公开(公告)号：US20180161205A1
公开(公告)日：2018-06-14
申请号：US15785122
申请日：2017-10-16
Applicant: DOSE MEDICAL CORPORATION
Inventor： Hosheng Tu , Barbara A. Niksch , David S. Haffner , Gregory T. Smedley , Olav B. Bergheim , Morteza Gharib , Richard A. Hill , Thomas W. Burns
CPC classification number: A61F9/00781 , A61F9/0017 , A61F2250/0067 , A61L27/54 , A61L2300/258 , A61L2300/41 , A61L2300/414 , A61L2300/416 , A61L2300/42 , A61L2430/16 , A61M27/002
Abstract: Implants and methods for treating ocular disorders are provided. One method involves introducing an implant into an anterior chamber of an eye. The implant is implanted into eye tissue adjacent the anterior chamber such that a proximal end of the implant resides in the anterior chamber following implantation. A therapeutic agent is eluted from the implant into the eye. Desirably, the release of the therapeutic agent from the implant is controlled. The controlled release of the therapeutic agent can be at a chosen rate and/or for a selected duration which can be episodic or periodic. The therapeutic agent can be an antiproliferative agent, an anti-inflammatory drug, or a compound for treating glaucoma or ocular hypertension.
-
公开(公告)号：US09066782B2
公开(公告)日：2015-06-30
申请号：US13716763
申请日：2012-12-17
Applicant: DOSE MEDICAL CORPORATION
Inventor： Hosheng Tu , Barbara A Niksch , David S Haffner , Gregory T Smedley , Olav B Bergheim , Morteza Gharib , Richard A. Hill , Thomas W. Burns
CPC classification number: A61F9/00781 , A61F9/0017 , A61F2250/0067 , A61L27/54 , A61L2300/258 , A61L2300/41 , A61L2300/414 , A61L2300/416 , A61L2300/42 , A61L2430/16 , A61M27/002
Abstract: Implants and methods for treating ocular disorders are provided. One method involves introducing an implant into an anterior chamber of an eye. The implant is implanted into eye tissue adjacent the anterior chamber such that a proximal end of the implant resides in the anterior chamber following implantation. A therapeutic agent is eluted from the implant into the eye. Desirably, the release of the therapeutic agent from the implant is controlled. The controlled release of the therapeutic agent can be at a chosen rate and/or for a selected duration which can be episodic or periodic. The therapeutic agent can be an antiproliferative agent, an anti-inflammatory drug, or a compound for treating glaucoma or ocular hypertension.
Abstract translation: 提供了用于治疗眼部疾病的植入物和方法。 一种方法是将植入物引入眼睛的前房。 将植入物植入邻近前房的眼组织中，使植入物的近端位于植入后的前房。 治疗剂从植入物中洗脱到眼睛中。 理想地，治疗剂从植入物的释放受到控制。 治疗剂的受控释放可以是选择的速率和/或选择的持续时间，其可以是情景性的或周期性的。 治疗剂可以是抗增生剂，抗炎药或治疗青光眼或高眼压症的化合物。
-
公开(公告)号：US09789001B2
公开(公告)日：2017-10-17
申请号：US14754458
申请日：2015-06-29
Applicant: DOSE MEDICAL CORPORATION
Inventor： Hosheng Tu , Barbara A. Niksch , David S. Haffner , Gregory T. Smedley , Olav B. Bergheim , Morteza Gharib , Richard A. Hill , Thomas W. Burns
CPC classification number: A61F9/00781 , A61F9/0017 , A61F2250/0067 , A61L27/54 , A61L2300/258 , A61L2300/41 , A61L2300/414 , A61L2300/416 , A61L2300/42 , A61L2430/16 , A61M27/002
Abstract: Implants and methods for treating ocular disorders are provided. One method involves introducing an implant into an anterior chamber of an eye. The implant is implanted into eye tissue adjacent the anterior chamber such that a proximal end of the implant resides in the anterior chamber following implantation. A therapeutic agent is eluted from the implant into the eye. Desirably, the release of the therapeutic agent from the implant is controlled. The controlled release of the therapeutic agent can be at a chosen rate and/or for a selected duration which can be episodic or periodic. The therapeutic agent can be an antiproliferative agent, an anti-inflammatory drug, or a compound for treating glaucoma or ocular hypertension.
-
公开(公告)号：US20160175151A1
公开(公告)日：2016-06-23
申请号：US14754458
申请日：2015-06-29
Applicant: DOSE MEDICAL CORPORATION
Inventor： Hosheng Tu , Barbara A. Niksch , David S. Haffner , Gregory T. Smedley , Olav B. Bergheim , Morteza Gharib , Richard A. Hill , Thomas W. Burns
IPC: A61F9/007
CPC classification number: A61F9/00781 , A61F9/0017 , A61F2250/0067 , A61L27/54 , A61L2300/258 , A61L2300/41 , A61L2300/414 , A61L2300/416 , A61L2300/42 , A61L2430/16 , A61M27/002
Abstract: Implants and methods for treating ocular disorders are provided. One method involves introducing an implant into an anterior chamber of an eye. The implant is implanted into eye tissue adjacent the anterior chamber such that a proximal end of the implant resides in the anterior chamber following implantation. A therapeutic agent is eluted from the implant into the eye. Desirably, the release of the therapeutic agent from the implant is controlled. The controlled release of the therapeutic agent can be at a chosen rate and/or for a selected duration which can be episodic or periodic. The therapeutic agent can be an antiproliferative agent, an anti-inflammatory drug, or a compound for treating glaucoma or ocular hypertension.
Abstract translation: 提供了用于治疗眼部疾病的植入物和方法。 一种方法是将植入物引入眼睛的前房。 将植入物植入邻近前房的眼组织中，使植入物的近端位于植入后的前房。 治疗剂从植入物中洗脱到眼睛中。 理想地，治疗剂从植入物的释放受到控制。 治疗剂的受控释放可以是选择的速率和/或选择的持续时间，其可以是情景性的或周期性的。 治疗剂可以是抗增生剂，抗炎药或治疗青光眼或高眼压症的化合物。
